Advanced Metastatic Nsclc clinical trials

Explore recruiting advanced metastatic nsclc clinical trials.

Recruiting advanced metastatic nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Metastatic Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

Bulgaria, Hungary, Poland, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non Small Cell Lung Cancer

Portugal, Hungary, Italy, Belgium, Germany, Spain +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, multisite, open-label, trial of pumitamig (BNT327) in combination with standard-of-care chemotherapy in first-line and second-line non-small-cell lung cancer (NSCLC)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non small Cell Lung Cancers, Negative for PD L1, and Positive for KRAS p.G12C (CodeBreaK 202)

Poland, Greece, Belgium, Portugal, Hungary, Netherlands +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Advanced Metastatic Nsclc trials by city

Advanced Metastatic Nsclc in Toronto Advanced Metastatic Nsclc in Vancouver Advanced Metastatic Nsclc in Montreal Advanced Metastatic Nsclc in Calgary Advanced Metastatic Nsclc in Edmonton Advanced Metastatic Nsclc in Ottawa Advanced Metastatic Nsclc in Winnipeg Advanced Metastatic Nsclc in Quebec City Advanced Metastatic Nsclc in Hamilton Advanced Metastatic Nsclc in Kitchener Advanced Metastatic Nsclc in London Advanced Metastatic Nsclc in Halifax Advanced Metastatic Nsclc in New York Advanced Metastatic Nsclc in Los Angeles Advanced Metastatic Nsclc in Chicago Advanced Metastatic Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease